Methadone and Ketamine for Neuropathic Pain Treatment
CompletedPhase 4NCT02233452
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Methadone and ketamine are effective for neuropathic pain management. However, the benefits of the association of both drugs are uncertain. Here, the investigators conducted a randomized, double-blind, in parallel, active controlled clinical trial to test the hypothesis that methadone combined ketamine (methadone/ketamine) is more effective than methadone or ketamine alone in reducing neuropathic pain.
Study details
- Official title
- Management of Neuropathic Chronic Pain With Methadone Combined With Ketamine: Randomized, Double Blind, Active-controlled Clinical Trial
- Conditions
- Interventions
- Drug: Methadone
- Drug: Ketamine
- Drug: Methadone plus Ketamine
- Sponsor
- Universidade Federal de Santa Maria
- Collaborators
- Santa Casa de Misericórdia de Belo Horizonte; Hospital de Clinicas de Porto Alegre
- Start date
- 2012-01
- Primary completion
- 2012-08
- Sex
- All
- Age range
- from 22 Years to 77 Years
- Results posted
- No results posted in this snapshot
- Countries
- Brazil
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * patients complaining of pain for more than 6 months with neuropathic pain poorly responsive to drugs used to treat neuropathic pain (i.e. opioid, non-opioid, anticonvulsants, antidepressants), who were 22 to 77 years old Exclusion Criteria: * patients with a history of severe psychiatric disorder, * misuse of illegal drugs or * hepatic disease
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02233452